scispace - formally typeset
K

Kathrin S. Michelsen

Researcher at Cedars-Sinai Medical Center

Publications -  64
Citations -  7302

Kathrin S. Michelsen is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: TLR4 & Inflammation. The author has an hindex of 35, co-authored 59 publications receiving 6837 citations. Previous affiliations of Kathrin S. Michelsen include Humboldt University of Berlin & University of California, Los Angeles.

Papers
More filters
Journal ArticleDOI

Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E

TL;DR: An important role for TLR4 and MyD88 signaling in atherosclerosis in a hypercholesterolemic mouse model is suggested, providing a pathophysiologic link between innate immunity, inflammation, and atherogenesis.
Journal ArticleDOI

Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis

TL;DR: DSS treatment of TLR4-/- mice was associated with striking reduction in acute inflammatory cells compared with wild-type mice despite similar degrees of epithelial injury, suggesting that this is the dominant downstream pathway.
Journal ArticleDOI

Human Intestinal Epithelial Cells Are Broadly Unresponsive to Toll-Like Receptor 2-Dependent Bacterial Ligands: Implications for Host-Microbial Interactions in the Gut

TL;DR: The relative absence of TLR2 protein expression by IEC and high level of Tollip expression may be important in preventing chronic proinflammatory cytokine secretion in response to commensal Gram-positive bacteria in the gut.
Journal ArticleDOI

HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression

TL;DR: Evidence is provided for the molecular and cellular mechanisms that support the rationale for the clinical implementation of antibrain cancer immunotherapies in combination with tumor killing approaches in order to elicit effective antitumor immune responses, and thus, will impact clinical neuro-oncology practice.